Brief: Eloxx Pharmaceuticals Provides Update On Progress Of Phase 2 Clinical Programs For Elx-02 And ERSG Pipeline
14/01/2020 20:20
Jan 14 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS PROVIDES UPDATE ON PROGRESS OF ITS
PHASE 2
CLINICAL PROGRAMS FOR ELX-02 AND ERSG PIPELINE AT BIOTECH
SHOWCASE™
* ELOXX PHARMACEUTICALS - POSITIVE PHASE 2 TOPLINE DATA
REPORTED
FOR ELX-02 IN NEPHROPATHIC CYSTINOSIS FROM FIRST TREATMENT
COHORT
* ELOXX PHARMACEUTICALS INC - TOPLINE RESULTS FOR ELX-02
EXPECTED
DURING FIRST HALF OF 2020
* ELOXX PHARMACEUTICALS - PHASE 2 CYSTIC FIBROSIS PROGRAM
FOR
ELX-02 EXPECTED TO BE FULLY ENROLLED IN Q1 OF 2020
* ELOXX PHARMACEUTICALS INC - ERSG PIPELINE CONTINUES TO
PROGRESS
* ELOXX PHARMACEUTICALS - IN STUDY, ELX-02 WAS GENERALLY
WELL
TOLERATED WITH NO DEATHS, NEPHROTOXICITY, OTOTOXICITY OR SERIOUS
ADVERSE EVENTS
Source text for Eikon: ID:nGNX5qkpt0
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome